Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

doi:10.1128/AAC.01264-21

. 2021 Oct 18;65(11):e0126421.

doi: 10.1128/AAC.01264-21. Epub 2021 Sep 7.

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

Dee Shortridge¹, S J Ryan Arends¹, Jennifer M Streit¹, Mariana Castanheira¹

Affiliations

PMID: 34491809
PMCID: PMC8522744
DOI: 10.1128/AAC.01264-21

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

Dee Shortridge et al. Antimicrob Agents Chemother. 2021.

. 2021 Oct 18;65(11):e0126421.

doi: 10.1128/AAC.01264-21. Epub 2021 Sep 7.

Authors

Dee Shortridge¹, S J Ryan Arends¹, Jennifer M Streit¹, Mariana Castanheira¹

Affiliation

¹ JMI Laboratoriesgrid.419652.d, North Liberty, Iowa, USA.

PMID: 34491809
PMCID: PMC8522744
DOI: 10.1128/AAC.01264-21

Abstract

The minocycline susceptibility of 3,856 isolates including Burkholderia, Achromobacter, Alcaligenes, Aeromonas, and Stenotrophomonas maltophilia from the SENTRY surveillance (2014 to 2019) were analyzed. The susceptibilities of these species (%S) were Achromobacter spp. (n = 411; 92.6%), Burkholderia cepacia species complex (n = 199; 85.9%), Aeromonas spp. (n = 127; 99.2%), Chryseobacterium spp. (n = 59; 94.9%), Alcaligenes faecalis (n = 42; 88.1%), and S. maltophilia (n = 2,287; 99.5%). These data suggest that minocycline is a useful treatment option for infections caused by unusual Gram-negative pathogens.

Keywords: Achromobacter; Aeromonas; minocycline; surveillance.

PubMed Disclaimer

Cited by

Clinical challenges treating Stenotrophomonas maltophilia infections: an update.
Mojica MF, Humphries R, Lipuma JJ, Mathers AJ, Rao GG, Shelburne SA, Fouts DE, Van Duin D, Bonomo RA. Mojica MF, et al. JAC Antimicrob Resist. 2022 May 5;4(3):dlac040. doi: 10.1093/jacamr/dlac040. eCollection 2022 Jun. JAC Antimicrob Resist. 2022. PMID: 35529051 Free PMC article. Review.
Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study.
Nair AP, Sasi S, Al Maslamani M, Al-Khal A, Chacko K, Deshmukh A, Abukhattab M. Nair AP, et al. Cureus. 2022 Mar 17;14(3):e23263. doi: 10.7759/cureus.23263. eCollection 2022 Mar. Cureus. 2022. PMID: 35449666 Free PMC article.
In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?
Beauruelle C, Lamoureux C, Mashi A, Ramel S, Le Bihan J, Ropars T, Dirou A, Banerjee A, Tandé D, Le Bars H, Héry-Arnaud G. Beauruelle C, et al. Microorganisms. 2021 Nov 30;9(12):2473. doi: 10.3390/microorganisms9122473. Microorganisms. 2021. PMID: 34946075 Free PMC article.

References

1. Gabrielaite M, Bartell JA, Norskov-Lauritsen N, Pressler T, Nielsen FC, Johansen HK, Marvig RL. 2021. Transmission and antibiotic resistance of Achromobacter in cystic fibrosis. J Clin Microbiol 59:e02911-20. doi:10.1128/JCM.02911-20. - DOI - PMC - PubMed
1. Spencer HK, Spitznogle SL, Borjan J, Aitken SL. 2020. An overview of the treatment of less common non-lactose-fermenting Gram-negative bacteria. Pharmacotherapy 40:936–951. - PubMed
1. Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. 2020. Achromobacter infections and treatment options. Antimicrob Agents Chemother 64:e01025-20. doi:10.1128/AAC.01025-20. - DOI - PMC - PubMed
1. Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Norskov-Lauritsen N. 2011. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 10:466–469. doi:10.1016/j.jcf.2011.07.004. - DOI - PubMed
1. Coward A, Kenna DTD, Woodford N, Turton JF, UK CF Surveillance Working Group. 2020. Structured surveillance of Achromobacter, Pandoraea, and Ralstonia species from patients in England with cystic fibrosis. J Cyst Fibros 19:388–393. doi:10.1016/j.jcf.2019.11.005. - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

Melinta Therapeutics

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] Gabrielaite M, Bartell JA, Norskov-Lauritsen N, Pressler T, Nielsen FC, Johansen HK, Marvig RL. 2021. Transmission and antibiotic resistance of Achromobacter in cystic fibrosis. J Clin Microbiol 59:e02911-20. doi:10.1128/JCM.02911-20. - DOI - PMC - PubMed

[2] Gabrielaite M, Bartell JA, Norskov-Lauritsen N, Pressler T, Nielsen FC, Johansen HK, Marvig RL. 2021. Transmission and antibiotic resistance of Achromobacter in cystic fibrosis. J Clin Microbiol 59:e02911-20. doi:10.1128/JCM.02911-20. - DOI - PMC - PubMed

[3] Spencer HK, Spitznogle SL, Borjan J, Aitken SL. 2020. An overview of the treatment of less common non-lactose-fermenting Gram-negative bacteria. Pharmacotherapy 40:936–951. - PubMed

[4] Spencer HK, Spitznogle SL, Borjan J, Aitken SL. 2020. An overview of the treatment of less common non-lactose-fermenting Gram-negative bacteria. Pharmacotherapy 40:936–951. - PubMed

[5] Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. 2020. Achromobacter infections and treatment options. Antimicrob Agents Chemother 64:e01025-20. doi:10.1128/AAC.01025-20. - DOI - PMC - PubMed

[6] Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. 2020. Achromobacter infections and treatment options. Antimicrob Agents Chemother 64:e01025-20. doi:10.1128/AAC.01025-20. - DOI - PMC - PubMed

[7] Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Norskov-Lauritsen N. 2011. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 10:466–469. doi:10.1016/j.jcf.2011.07.004. - DOI - PubMed

[8] Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Norskov-Lauritsen N. 2011. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros 10:466–469. doi:10.1016/j.jcf.2011.07.004. - DOI - PubMed

[9] Coward A, Kenna DTD, Woodford N, Turton JF, UK CF Surveillance Working Group. 2020. Structured surveillance of Achromobacter, Pandoraea, and Ralstonia species from patients in England with cystic fibrosis. J Cyst Fibros 19:388–393. doi:10.1016/j.jcf.2019.11.005. - DOI - PubMed

[10] Coward A, Kenna DTD, Woodford N, Turton JF, UK CF Surveillance Working Group. 2020. Structured surveillance of Achromobacter, Pandoraea, and Ralstonia species from patients in England with cystic fibrosis. J Cyst Fibros 19:388–393. doi:10.1016/j.jcf.2019.11.005. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

Affiliation

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous